Focus: Regenxbio is a gene therapy-focused biotechnology company headquartered in Rockville, MD, developing AAV-based treatments for rare genetic and retinal diseases. The company operates across multiple therapeutic areas including oncology and gene therapy with a pipeline spanning lysosomal storage disorders, retinal conditions, and muscular dystrophy.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Regenxbio offers gene therapy specialization and pipeline momentum, but limited scale and hiring velocity indicate this is a targeted opportunity for early-career or specialized roles rather than a broad growth employer.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Regenxbio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Regenxbio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles